用药错误致害与住院费用及住院时长的关联:利用收费主数据(chargemaster)的分析
该回顾性单中心研究利用自愿事件报告系统数据与诊断编码,识别2014年4月至2015年5月某学术医学中心住院患者中导致伤害的用药错误,并按入院时段、诊断相关组及年龄性别匹配对照。242例与3279例对照分析显示,致害用药错误组的总住院费用中位数(19444美元)与住院时长中位数均显著高于对照组。
要点
- 致害用药错误涉及的主要药物类别为化疗药(38%)、糖皮质激素(14%)和阿片类(11%)。
- 致害用药错误组总住院费用中位数19444美元,对照组17173美元,差异有统计学意义(p=0.044)。
- 致害用药错误组住院时长中位数亦显著更长(p=0.005)。
核心结论
- 在学术医学中心,记录有致害用药错误的住院病例,其总住院费用中位数和住院时长中位数均显著高于未记录致害用药错误的住院病例。
研究设计与样本
- 回顾性单中心研究,纳入2014年4月至2015年5月某学术医学中心住院患者,利用自愿事件报告系统数据和诊断编码识别用药错误。
- 共416例住院病例评估纳入,最终242例致害用药错误病例与3279例对照按入院时段、诊断相关组、年龄和性别匹配。
- 采用独立双样本Mann-Whitney U检验分析总住院费用与住院时长。
主要发现
- 致害用药错误涉及的主要药物类别为化疗药(38%)、糖皮质激素(14%)和阿片类(11%)。
- 致害用药错误组总住院费用中位数19444美元(IQR 13481–40580美元),对照组17173美元(IQR 12500–27125美元),差异有统计学意义(p=0.044)。
- 致害用药错误组住院时长中位数显著更长(p=0.005)。
临床怎么用
- 可提示临床药学服务关注化疗药、糖皮质激素和阿片类等高风险药物的用药错误防范,以降低致害事件及相应住院经济负担。
- chargemaster数据可作为机构层面量化致害用药错误经济影响的辅助数据来源。
局限性
- 单中心回顾性设计,结果外推需谨慎。
- 用药错误识别依赖自愿事件报告系统与诊断编码,可能存在漏报或错分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Results of an analysis of the economic impact of adverse drug events (ADEs) resulting in patient harm on hospitalization costs and length of stay (LOS) are reported. METHODS: In a retrospective single-site study, medication errors among patients admitted to an academic medical center during the period April 2014-May 2015 were identified using voluntary event reporting system data and diagnosis codes. Hospitalization cases involving documented ADEs resulting in harm, as defined on a widely used medication error classification index, were matched with control cases by admission period, diagnosis-related group, and patient age and sex. Total hospitalization costs and LOS in the study groups were analyzed using an independent 2-sample Mann-Whitney U test. RESULTS: Among 416 hospitalization cases evaluated for inclusion in the study, 242 were matched with 3,279 control cases for analysis. The primary drug classes implicated in the evaluated medication errors included chemotherapy agents (38%), corticosteroids (14%), and opioids (11%). Total hospitalization costs differed significantly (p = 0.044) between patients who experienced ADEs resulting in harm (median, $19,444; interquartile range [IQR], $13,481-$40,580) and those who did not (median, $17,173; IQR, $12,500-$27,125); the former group also had a significantly (p = 0.005) longer median LOS. CONCLUSION: Chargemaster data for an academic medical center revealed that the median total hospitalization cost and LOS were significantly greater for hospitalizations during which a harm-causing medication error was recorded versus hospitalizations during which harm-causing medication errors were not recorded.
引用
- McCarthy BC, Tuiskula KA, Driscoll TP, et al. Medication errors resulting in harm: Using chargemaster data to determine association with cost of hospitalization and length of stay. Am J Health Syst Pharm. 2017. PMID: 29167147. doi:10.2146/ajhp160848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。